Michael Makris on Rising Malignancy Concerns After Hemophilia Gene Therapy: Key Challenges Highlighted in NEJM
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, posted on LinkedIn:
”There is an interesting discussion about the issue of malignancy in persons with haemophilia who have had gene therapy in the New England Journal this week.
The number of malignancies is increasing as more patients undergo gene therapy.
The key issues are:
a) Need for a standardised set of investigations
b) Need for advice on what tissue sample to collect and how to store them, to allow for the more specialised investigations
c) The interpretation of the results
d) Payment for these very expensive investigations. Manufacturers have funded these so far because most of the cases were seen in the clinical trials, but will they continue to fund it long term? ”
Stay updated with Hemostasis Today.
-
Sep 14, 2025, 11:17Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
-
Sep 13, 2025, 13:32Beta Thalassemia Major After Splenectomy: Setareh Sheikhi Reports Striking nRBC Surge Reports Striking nRBC Surge
-
Sep 13, 2025, 13:26Global Blood and Plasma Collections and Use 2023–2024: Trends, Regulations, and Market Insights
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 14, 2025, 14:36Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk
-
Sep 14, 2025, 12:37Ivan Budnik Highlights New Framework for Thrombus Resolution Analysis in Mouse IVC Stenosis Model
-
Sep 14, 2025, 04:16F8 Gene Variants Affect Desmopressin Response in Female Hemophilia A Carriers
-
Sep 13, 2025, 13:35Michael Makris on Rising Malignancy Concerns After Hemophilia Gene Therapy: Key Challenges Highlighted in NEJM
-
Sep 13, 2025, 13:20Giulia Simini: Our Review on the Hepatic Life Cycle of AAV is Now Available in JTH
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 14, 2025, 06:39Abdul Mannan on Factor VIII Aurora: First Natural Gain-of-Function Mutation in Haemophilia A
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 13, 2025, 06:49Emna Gouider Belhadjali on the Role of NMOs in Advocating for Equitable Access to Diagnosis for WGBDs
-
Sep 12, 2025, 09:30Arun V J Explains How Blood Donation Rules Differ Worldwide and Why Your Donation Saves Lives Everywhere